Triplet Therapeutics
Biotechnology ResearchMassachusetts, United States11-50 Employees
Triplet Therapeutics is a Cambridge, Massachusetts–based biotechnology company focused on repeat expansion disorders (REDs), a group of genetic diseases that includes Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial ALS. The company translates patient genetics into therapeutics and uses its thRED Engine to develop a single oligonucleotide designed to modulate the DNA Damage Response pathway with the potential to treat multiple REDs. By targeting a shared pathway across REDs, the approach aims to address a broad patient population affected by these conditions. Within the broader biotechnology research landscape, Triplet Therapeutics pursues a unified approach to REDs, aiming to benefit a sizable patient population. In 2020 the company launched SHIELD-HD, an international observational natural history study of Huntington’s disease to inform future drug trials. Based in Cambridge, the organization is a relatively small biotechnology company contributing to the field’s ongoing exploration of genetic-driven therapies.
1-888-653-2347 
support@leadiq.com 
